291 related articles for article (PubMed ID: 22802311)
1. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.
Hultcrantz M; Kristinsson SY; Andersson TM; Landgren O; Eloranta S; Derolf AR; Dickman PW; Björkholm M
J Clin Oncol; 2012 Aug; 30(24):2995-3001. PubMed ID: 22802311
[TBL] [Abstract][Full Text] [Related]
2. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
[TBL] [Abstract][Full Text] [Related]
3. Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
Roaldsnes C; Holst R; Frederiksen H; Ghanima W
Eur J Haematol; 2017 Jan; 98(1):85-93. PubMed ID: 27500783
[TBL] [Abstract][Full Text] [Related]
4. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
5. Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.
Hultcrantz M; Ravn Landtblom A; Andréasson B; Samuelsson J; Dickman PW; Kristinsson SY; Björkholm M; Andersson TM
J Intern Med; 2020 Apr; 287(4):448-454. PubMed ID: 31927786
[TBL] [Abstract][Full Text] [Related]
6. Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
Price GL; Davis KL; Karve S; Pohl G; Walgren RA
PLoS One; 2014; 9(3):e90299. PubMed ID: 24618579
[TBL] [Abstract][Full Text] [Related]
7. CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.
Kim SY; Im K; Park SN; Kwon J; Kim JA; Lee DS
Am J Clin Pathol; 2015 May; 143(5):635-44. PubMed ID: 25873496
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey.
Mesa R; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Boyle J; Mascarenhas JO
BMC Cancer; 2016 Feb; 16():167. PubMed ID: 26922064
[TBL] [Abstract][Full Text] [Related]
9. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
10. Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study.
Hultcrantz M; Wilkes SR; Kristinsson SY; Andersson TM; Derolf ÅR; Eloranta S; Samuelsson J; Landgren O; Dickman PW; Lambert PC; Björkholm M
J Clin Oncol; 2015 Jul; 33(20):2288-95. PubMed ID: 26033810
[TBL] [Abstract][Full Text] [Related]
11. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
12. The Epidemiology of Myeloproliferative Neoplasms in New Zealand between 2010 and 2017: Insights from the New Zealand Cancer Registry.
Varghese C; Immanuel T; Ruskova A; Theakston E; Kalev-Zylinska ML
Curr Oncol; 2021 Apr; 28(2):1544-1557. PubMed ID: 33919650
[TBL] [Abstract][Full Text] [Related]
13. Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Srour SA; Devesa SS; Morton LM; Check DP; Curtis RE; Linet MS; Dores GM
Br J Haematol; 2016 Aug; 174(3):382-96. PubMed ID: 27061824
[TBL] [Abstract][Full Text] [Related]
14. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases.
Dentali F; Ageno W; Rumi E; Casetti I; Poli D; Scoditti U; Maffioli M; di Minno MN; Caramazza D; Pietra D; De Stefano V; Passamonti F
Thromb Res; 2014 Jul; 134(1):41-3. PubMed ID: 24787989
[TBL] [Abstract][Full Text] [Related]
15. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative neoplasms in the young: Mayo Clinic experience with 361 patients age 40 years or younger.
Szuber N; Vallapureddy RR; Penna D; Lasho TL; Finke C; Hanson CA; Ketterling RP; Pardanani A; Gangat N; Tefferi A
Am J Hematol; 2018 Dec; 93(12):1474-1484. PubMed ID: 30157297
[TBL] [Abstract][Full Text] [Related]
17. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.
Ahlstrand E; Samuelsson J; Lindgren M; Pettersson H; Liljeholm M; Ravn-Landtblom A; Scheding S; Andréasson B
Eur J Haematol; 2020 Mar; 104(3):271-278. PubMed ID: 31863513
[TBL] [Abstract][Full Text] [Related]
18. Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.
Hultcrantz M; Björkholm M; Dickman PW; Landgren O; Derolf ÅR; Kristinsson SY; Andersson TML
Ann Intern Med; 2018 Mar; 168(5):317-325. PubMed ID: 29335713
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology of the classical myeloproliferative neoplasms: The four corners of an expansive and complex map.
Shallis RM; Wang R; Davidoff A; Ma X; Podoltsev NA; Zeidan AM
Blood Rev; 2020 Jul; 42():100706. PubMed ID: 32517877
[TBL] [Abstract][Full Text] [Related]
20. Highly increased risk of fracture in patients with myeloproliferative neoplasm.
Johansson P; Kristjansdottir HL; Johansson H; Jakir A; Mellström D; Lewerin C
Leuk Lymphoma; 2021 Jan; 62(1):211-217. PubMed ID: 32909485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]